Positive role of macaque cytotoxic T lymphocytes during SIV infection: decrease of cellular viremia and increase of asymptomatic clinical period.
We have measured cellular viremia and observed clinical outcome of macaques from two cohorts, the first including 12 macaques infected by SIVmac251 and the second including 12 macaques immunized by lipopeptides and then challenged by SIVmac251. In the first cohort (SIV-infected macaques), 3 patterns of CTL responders were determined: high, low and non-responders. In the macaques belonging to pattern of low and non-responders, cellular viremia, measured by growing the virus from PBMC, was continuously high during the first 6 months after infection, and five macaques developed AIDS within 14.4 +/- 7.7 months. Conversely, in the six high-responder macaques, cellular viremia was constantly low and only one macaque developed AIDS at 19 months, the five others being alive at 24 months. After immunization with lipopeptides, 7/12 macaques showed CTL responses and among these, after SIV challenge, cellular viremia was continually low, and no disease was observed at 22 months of follow-up. Conversely, the five non-responder macaques displayed persistent high viremia and macaques developed AIDS within 12.6 +/- 2.9 months after SIV challenge. These data strongly suggest that the presence of cytotoxic responses is inversely correlated with cellular viremia and correlated with overall survival and thus in an important component of the immune response in vaccinated individuals. It supports the idea that a strengthening of the CTL responses, if possible, might be beneficial in HIV-infected human beings.
Villada
I B
IB
Institut Cochin de Génétique Moléculaire, Laboratoire d'Immunologie des Pathologies Infectieuses et Tumorales, Université René Descartes, Hôpital Cochin, Paris, France.
Mortara
L
L
Aubertin
A M
AM
Gras-Masse
H
H
Lévy
J P
JP
Guillet
J G
JG
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D018450:Disease Progression; D015683:Gene Products, gag / Q000276:immunology; D015693:Gene Products, nef / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000821:virology; D008074:Lipoproteins / Q000276:immunology; D008253:Macaca mulatta; D009500:Neutralization Tests; D016097:Simian Acquired Immunodeficiency Syndrome / Q000175:diagnosis / Q000276:immunology*; D015302:Simian Immunodeficiency Virus / Q000254:growth & development / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014611:Vaccination; D019562:Viral Load; D014766:Viremia / Q000276:immunology*
D000914:Antibodies, Viral; D015683:Gene Products, gag; D015693:Gene Products, nef; D008074:Lipoproteins